ClinicalTrials.Veeva

Menu

Macular Pigment Optical Density in Primary Angle-closure Disease

Sun Yat-sen University logo

Sun Yat-sen University

Status

Enrolling

Conditions

Macular Pigment Optical Density
Glaucoma
Glaucoma, Angle-Closure

Treatments

Other: Ocular examination

Study type

Observational

Funder types

Other

Identifiers

NCT05251792
2020KYPJ82

Details and patient eligibility

About

Glaucoma is the leading cause of irreversible blindness in the world, and primary angle-closure glaucoma (PACG) is the most important type of glaucoma in Asia. Primary angle closure disease (PACD) is a group of diseases related to PACG, and the pathogenesis is still unclear. Macular pigment has the functions of filtering short-wavelength waves and anti-oxidation, which are related to visual function. Previous studies have found that the macular pigment density (MPOD) is significantly reduced in primary open-angle glaucoma. This project uses the single-wavelength reflection method to measure MPOD, observes the characteristics of PACD and the normal control group's changes in retinal MPOD, and explains the relationship between PACD's MPOD changes and angle-closure glaucoma optic nerve damage

Full description

Observation index: Visual acuity,Intraocular pressure,Ophthalmoscope,MPOD,Visual field and OCT.

Inspection parameters of OCT:

  1. Retinal nerve fiber layer thickness
  2. Ganglion cell complex thickness
  3. Mean thickness of the central retina
  4. Mean defect

Enrollment

60 estimated patients

Sex

All

Ages

40 to 90 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Experimental group:
  • (1) According to the diagnostic criteria of PACD
  • (2)History of peripheral iridectomy or trabeculectomy
  • (3)Over 40
  • (4)Phakic eyes
  • (5)Intraocular pressure is less than 21mmhg, more than one week
  • (6)Eyes with clear optical media.
  • Control group:
  • (1)No history of glaucoma and other eye diseases
  • (2)Phakic eyes
  • (3)Over 40
  • (4)Intraocular pressure10~21mmHg

Exclusion criteria

  • (1)History of corneal diseases
  • (2)History of eye tumor or other ophthalmic surgery
  • (3)Cataract
  • (4)Taking supplements containing lutein within 6 months
  • (5)Snellen's visual acuity was less than 6 / 20,the diopter is beyond ± 6 degrees

Trial design

60 participants in 2 patient groups

Primary Angle Clousure Diseases Eyes
Description:
Over 40 years old, regardless of gender. Patients diagnosed with PACD (PACG or PAC or PACS) with phakic eyes. Peripheral iridectomy or trabeculectomy, more than 3 months after operation.
Treatment:
Other: Ocular examination
Matched Eyes
Description:
Healthy population matched by sex and age.
Treatment:
Other: Ocular examination

Trial contacts and locations

1

Loading...

Central trial contact

Chengguo Zuo, M.D,Ph.D; Zhihong Huang, M.D

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems